Researchers Identify Trigger and Mechanism in Type 1 Diabetes

Discovery Suggests Strategies for Preventing and Treating the Autoimmune Disease

APRIL 08, 2019

DENVER — Researchers at National Jewish Health have identified an elusive trigger of type 1 diabetes. A protein fragment formed in the pancreas activates the immune system’s T cells, leading them to attack and destroy beta cells, which produce insulin. Lack of insulin is a hallmark of type 1 diabetes.

The research, published in the April 5, 2019, issue of Science Immunology, solves a long-standing mystery about the specific molecule that triggers many cases of type 1 diabetes, and suggests strategies to prevent and treat the disease.

“These results provide important evidence about how molecules activate the autoimmune response in type 1 diabetes, how they are likely created and why the immune system is fooled into launching this misdirected attack against its own body,” said John Kappler, PhD, senior author and Professor of Biomedical Research at National Jewish Health.

Type 1 diabetes is an autoimmune disease in which the body’s immune system goes awry and begins attacking its own tissues. This misdirected attack is orchestrated by rogue T cells that mistakenly recognize the body’s own tissue as potentially harmful.

T cells sense the internal environment of the body through receptors on their surfaces. When these receptors fit and bind to a piece of a foreign protein and a molecule holding it on the surface of other cells, it becomes activated and launches an immune system T-cell response, resulting ultimately in the elimination of the invader.

Over the years, researchers have identified a number of pathogenic T cells in humans and mice that orchestrate the autoimmune attack in type 1 diabetes. Many of these T cells are triggered by the protein insulin. There has been considerable uncertainty and controversy, however, exactly what part of this protein the T cells recognize and why they might be triggered to attack the cells in the pancreas that produce insulin.

In the Science Immunology paper, the researchers report three crystal structures that show how human and mouse pathogenic T cells bind to fragments of insulin and the MHCII molecule that holds them on the cellular surface. The crystal structures demonstrate that an insulin fragment known as B:14-22 is the activator of these T cells. The structures cap almost a decade of work by Drs. Kappler, Dai and their colleagues to definitively prove how the B:14-22 fragment is an important trigger for type 1 diabetes in both species.

“These structures provide important knowledge about a major cause of type 1 diabetes and suggest potential targets and strategies for treating and preventing type 1 diabetes,” said Shaodong Dai, PhD, co-author on the paper.

However, to make the MHCII molecules, the protein fragments and the pathogenic T cells all fit snugly together, the researchers altered the protein fragment; they changed several of its nine core amino acids to improve greatly binding to the MHCII molecules and/or recognition by the T cells.

“When we altered the insulin fragments, they fit tightly, and in a way that activated the pathogenic T cells,” said Dr. Kappler. “We felt confident that the altered insulin fragments were the ones that triggered the autoimmune attack, but
we did not know how those changes might occur naturally in the body. We were stumped.”

A chance conversation with a colleague alerted Dr. Kappler to a natural recycling process in cells that might change the insulin fragments into forms that trigger type 1 diabetes. As proteins are broken apart and recycled in cells, fragments are sometimes fused back together in new configurations by a natural process called transpeptidation. Beta cells in the pancreas are especially susceptible to this fragment fusion because they constantly recycle insulin as part of the careful regulation of glucose metabolism.

Dr. Kappler and his colleagues looked at the amino acid sequence of insulin and found many possible breaks and reconnections that could produce amino acid sequences, similar to the ones in their crystals, which fit snugly in the MHCII molecule and activate the pathogenic T cells. They tested over a dozen of these possible fusion fragments with the pathogenic T cells in culture and found that many of them strongly stimulated the T cells, up to 500,000 times as effectively as the unaltered insulin fragment.

“The recycling process inside beta cells can produce many protein fragments that can activate the pathogenic T cells from both mice and humans to trigger type 1 diabetes,” said Yang Wang, PhD, first author on the paper. “We have finally identified the precise target for T cells that cause type 1 diabetes and identified a process that can produce those disease triggers.”

T cells mature in the thymus, where any of them that have receptors that bind to a naturally occurring protein in the body are eliminated. This helps prevents the immune system from attacking its own body. Dr. Kappler and his colleagues believe that the pathogenic T cells in type 1 diabetes mature and escape the thymus because they are not exposed to the fused insulin protein fragments in the thymus. When they come across those fragments in the pancreas, they mistake them for foreign invaders and launch an autoimmune attack against the beta cells that produce them.

**National Jewish Health** is the leading respiratory hospital in the nation. Founded 121 years ago as a nonprofit hospital, National Jewish Health today is the only facility in the world dedicated exclusively to groundbreaking medical research and treatment of patients with respiratory, cardiac, immune and related disorders. Patients and families come to National Jewish Health from around the world to receive cutting-edge, comprehensive, coordinated care. To learn more, visit the media resources page.

**Media Contacts**

Our team is available to arrange interviews, discuss events and story ideas.

**William Allstetter**
303.398.1002
allstetterw@njhealth.org

**Adam Dormuth**
303.398.1082
dormutha@njhealth.org